Maxim Group set a $7.00 target price on Can Fite Biopharma (NYSEAMERICAN:CANF) in a report published on Monday, January 8th. The brokerage currently has a buy rating on the biotechnology company’s stock.
“Weeks after the announcement of enrollment of the first patient in the P3 ACRobat study of Piclidenoson in RA, Can-Fite has announced a distribution agreement with Gebro Holdings GmBH for distribution in Spain, Switzerland, and Austria upon regulatory approval.”,” Maxim Group’s analyst commented.
Separately, HC Wainwright set a $6.00 target price on Can Fite Biopharma and gave the stock a buy rating in a report on Tuesday, October 31st.
TRADEMARK VIOLATION WARNING: This report was published by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/maxim-group-reiterates-buy-rating-for-can-fite-biopharma-canf/1819029.html.
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.